Bioenergy sales, which for Novozymes consists of enzyme sales for bioethanol production, showed an organic growth rate of 5 percent in the fourth quarter of 2018.
This is not quite as high as sales from the same quarter in 2017, which was booked at 14 percent. Novozymes is, however, impacted by large bioethanol inventories accumulated in the US.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for EnergyWatch has now started
With your free trial you get:
Full access to all locked articles on EnergyWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.